医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sanchaeman Launches Ready Meals Brand ‘Bibyeoyo’ for Korean Traditional Gondeure-Bap

2019年07月24日 PM09:00
このエントリーをはてなブックマークに追加


 

INJE, GANGWON-DO, South Korea

A traditional Korean food Gondeure-bap, which is the rice cooked with Korean thistle (Gondeure), is now available worldwide.

Sanchaeman Co., Ltd., a Korean food supplier that provides fresh foods made of farm products from Gangwon-do, has launched the Bibyeoyo, a pre-cooked Gondeure with which consumers make Gondeure-bap quick and easy.

Sanchaeman’s Bibyeoyo only uses blanched Gondeure from Gangwon-do without any chemical additives and contains fermented raw bellflower essence to add a deep flavor. Consumers just can pour the contents over a bowl of rice and mix well to make a delicious meal full of nutrition. It’s also a perfect fit for vegetarians.

Korean thistle, also known as Goryeo thistle, is a type of wild edible greens that has a unique light, smooth and aromatic flavor. It contains a variety of vitamins and beta carotene. It also boasts rich fiber content and low-calories.

When eaten blanched, steamed, or seasoned, the gondeure helps bowel movements to relieve constipation and improve skin health.

“Bibyeoyo is nutritious and convenient to eat. It’s the best food for busy modern people,” said Sang-mi Park, a president of Sanchaeman.

Sanchaeman’s Bibyeoyo has four types of flavor: earthy, a little spicy, Sanchaebibim, and Gangdoenjang.

It can be purchased from Kangwonmall, Gangwon-do’s specialty foods website: http://chan24.co.kr

View source version on businesswire.com: https://www.businesswire.com/news/home/20190724005039/en/

CONTACT

Sanchaeman Co., Ltd.

Sang-mi Park

+82-33-461-1062

tkdal7877@hanmail.net

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • LetsGetChecked、FDAのEUA承認を受けた在宅型コロナウイルス(COVID-19)検査用シュア・トラック・テストを発表
  • 欧盟委员会同意武田无需履行剥离夏尔后续化合物SHP647的承诺
  • Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time
  • Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML
  • Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS